Subclinical optic neuropathy in Fabry disease

REFERENCES

• Brady RO, Gal AE, Bradley RM, Martensson E, Warshaw AL, Laster L. Enzymatic defect in Fabry’s disease. Ceramidetrihexosidase deficiency. N Engl J Med. 1967;276:1163–1167.
   PubMed Web of Science ®Google Scholar
• Whybra C, Kampmann D, Willers I, Davies J, Winchester B, Kriegsmann J, Brühl K, Gal A, Bunge S, Beck M. Anderson-Fabry disease: clinical manifestations of disease in female heterozyotes. J Inherit Metab Dis. 2001;24:715–724.
   PubMed Web of Science ®Google Scholar
• Beck M, Ricci R, Widmer U, Dehout F, de Lorenzo AG, Kampmann C, Linhart A, Sunder-Plassmann G, Houge G, Ramaswami U, Gal A, Mehta A. Fabry disease: overall effects of agalsidase alfa treatment. Eur J Clin Invest. 2004;34:838–844.
   PubMed Web of Science ®Google Scholar
• Eng CM, Guffon N, Wilcox WR Germain DP, Lee P, Waldek S, Caplan L, Linthorst GE, Desnick RJ; International Collaborative Fabry Disease Study Group. Safety and efficacy of recombinant human alpha-galactosidase A – replacement therapy in Fabry’s disease. N Engl J Med. 2001;345:9–16.
   PubMed Web of Science ®Google Scholar
• Sher NA, Letson RD, Desnick RJ. The ocular manifestations in Fabry’s disease. Arch Ophthalmol. 1979;97:671–676.
   PubMedGoogle Scholar
• Sodi A, Ioannidis AS, Mehta A, Davey C, Beck M, Pitz S. Ocular manifestations of Fabry’s disease: data from the Fabry Outcome Survey. Br J Ophthalmol. 2007;91:210–214.
   PubMed Web of Science ®Google Scholar
• Orssaud C, Dufier J, Germain D. Ocular manifestations in Fabry disease: a survey of 32 hemizygous male patients. Ophthalmic Genet. 2003;24:129–139.
   PubMedGoogle Scholar
• Whybra C, Kampmann C, Krummenauer F, Ries M, Mengel E, Miebach E, Baehner F, Kim K, Bajbouj M, Schwarting A, Gal A, Beck M. The Mainz severity score index: a new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy. Clin Genet. 2004;65:299–307.
   PubMed Web of Science ®Google Scholar
• Brusini P, Filacordia S. Enhanced glaucoma staging system (GSS 2) for classifying functional damage in glaucoma. J Glaucoma. 2006;15:40–46.
   PubMed Web of Science ®Google Scholar
• Brusini P, Johnson CA. Staging functional damage in glaucoma: review of different classification methods. Surv Ophthalmol. 2007;52:156–179.
   PubMed Web of Science ®Google Scholar
• Bloomfield SE, David DS, Rubin AL. Eye findings in the diagnosis of Fabry’s disease. Patients with renal failure. JAMA. 1978;240:647–649.
   PubMed Web of Science ®Google Scholar
• Rahman AN. The ocular manifestations of hereditary dystopic lipidosis. Arch Ophthalmol. 1963;69:708–716.
   PubMedGoogle Scholar
• Ohkubo H. Several functional and fluorescein fundus angiographic findings in Fabry’s disease. Ophthalmologica. 1988;196:132–136.
   PubMed Web of Science ®Google Scholar
• Dantas MA, Fonseca RA, Kaga T, Spaide RF. Retinal and choroidal vascular changes in heterozygous Fabry disease. Retina. 2001;21:87–89.
   PubMed Web of Science ®Google Scholar
• Spaeth GL, Frost P. Fabry’s disease. Its ocular manifestations. Arch Ophthalmol. 1965;74:760–769.
   PubMedGoogle Scholar
• Velzeboer CMJ, de Groot WP. Ocular manifestations in angiokeratoma corporis diffusum (Fabry). Br J Ophthalmol. 1991;51:683–692.
   Google Scholar
• Abe H, Sakai T, Sawaguchi S, Hasegawa S, Takagi M, Yoshizawa T, Usui T, Horikawa Y. Ischemic optic neuropathy in a female carrier with Fabry’s disease. Ophthalmologica. 1992;205:83–88.
   PubMed Web of Science ®Google Scholar
• Tupprainen K, Collan Y, Rantanen T, Hollmen A. Fabry’s disease and cornea verticillata. A report of 3 cases. Acta ophthalmologica. 1981;59:674–682.
   Web of Science ®Google Scholar
• Andersen MVN, Dahl H, Fledelius H, Nielsen HN. Central artery occlusion in a patient with Fabry’s disease documented by scanning laser ophthalmoscopy. Acta ophthalmologica. 1994;72:635–638.
   PubMed Web of Science ®Google Scholar
• Sher NA, Reiff W, Letson RD, Desnick RJ. Central retinal artery occlusion complicating Fabry’s disease. Arch Ophthalmol. 1978;96:815–817.
   PubMedGoogle Scholar
• Utsumi K, Yamamoto N, Kase R, Takata T, Okumiya T, Saito H, Suzuki T, Uyama E, Sakuraba H. High incidence of thrombosis in Fabry’s disease., Internal Medicine. 1997;36:327–329.
   PubMed Web of Science ®Google Scholar
• Hirano K, Murata K, Miyagawa A, Terasaki H, Saigusa J, Nagasaka T, Kobayashi M. Histopathologic findings of cornea verticillata in a woman heterozygous for Fabry disease. Cornea. 2001;20:233–236.
   PubMed Web of Science ®Google Scholar
• Oto S, Kart H, Kadayifçilar S, Ozdemir N, Aydin P. Retinal vein occlusion in a woman with heterozygous Fabry’s disease. Eur J Ophthalmol. 1998;8:265–267.
   PubMed Web of Science ®Google Scholar
• Samiy N. Ocular features of Fabry disease: diagnosis of a treatable life-threatening disorder. Surv Ophthalmol. 2008;53:416–423.
   PubMed Web of Science ®Google Scholar
• Purvin V, Kawasaki A, Borruat FX. Optic neuropathy in patients using amiodarone. Arch Ophthalmol. 2006;124:696–701.
   PubMedGoogle Scholar
• Huismans H. [Bilateral edema of optic nerve (toxic edema) by therapy with chloroquine because of p.c.p]. Klin Mbl Augenheilk. 1982;181:36–37.
   PubMed Web of Science ®Google Scholar
• Ries M, Kim HJ, Zalewski CK, Mastroianni MA, Moore DF, Brady RO, Dambrosia JM, Schiffmann R, Brewer CC. Neuropathic and cerebrovascular correlates of hearing loss in Fabry disease. Brain. 2007;130:143–150.
   PubMed Web of Science ®Google Scholar
• Hegemann S, Hajioff D, Conti G, Beck M, Sunder-Plassmann G, Widmer U, Mehta A, Keilmann A. Hearing loss in Fabry disease: Data from the Fabry outcome survey. Eur J Clin Invest. 2006;36:654–662.
   PubMed Web of Science ®Google Scholar